Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers

Ron L.H. Handels, Stephanie J.B. Vos, Milica G. Kramberger, Vesna Jelic, Kaj Blennow, Mark van Buchem, Wiesje van der Flier, Yvonne Freund-Levi, Harald Hampel, Marcel Olde Rikkert, Ania Oleksik, Zvezdan Pirtosek, Philip Scheltens, Hilkka Soininen, Charlotte Teunissen, Magda Tsolaki, Asa K. Wallin, Bengt Winblad, Frans R.J. Verhey, Pieter Jelle Visser

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Introduction We aimed to determine the added value of cerebrospinal fluid (CSF) to clinical and imaging tests to predict progression from mild cognitive impairment (MCI) to any type of dementia. Methods The risk of progression to dementia was estimated using two logistic regression models based on 250 MCI participants: the first included standard clinical measures (demographic, clinical, and imaging test information) without CSF biomarkers, and the second included standard clinical measures with CSF biomarkers. Results Adding CSF improved predictive accuracy with 0.11 (scale from 0–1). Of all participants, 136 (54%) had a change in risk score of 0.10 or higher (which was considered clinically relevant), of whom in 101, it was in agreement with their dementia status at follow-up. Discussion An individual person's risk of progression from MCI to dementia can be improved by relying on CSF biomarkers in addition to recommended clinical and imaging tests for usual care.

Original languageEnglish
Pages (from-to)903-912
Number of pages10
JournalAlzheimer's and Dementia
Volume13
Issue number8
DOIs
Publication statusPublished - 1 Aug 2017

Keywords

  • Alzheimer's disease
  • Conversion
  • Dementia
  • Mild cognitive impairment
  • Predict
  • Prognosis
  • Progression
  • Reclassification
  • Risk
  • Risk prediction model

Cite this